Core Insights - The article discusses the strategic investment by Xianjian Technology in Jianhu Medical, highlighting the importance of this partnership in enhancing the domestic electrophysiology market and creating a comprehensive atrial fibrillation treatment solution [2][15][16] Investment Details - Xianjian Technology announced an investment of 150 million RMB in Jianhu Medical for a 30% stake, with the first phase involving an immediate transfer of 22.22% equity [2][4] - The partnership grants Xianjian exclusive rights for cooperation and distribution of Jianhu's electrophysiology products, including a three-dimensional mapping system and PFA ablation platform [4][16] Company Background - Jianhu Medical, established in 2021, focuses on next-generation cardiac electrophysiology imaging and energy treatment platforms, led by a team with experience from multinational companies [6][15] - The company has developed a comprehensive product line, including a three-dimensional dielectric mapping system and a nanosecond PFA ablation system, showcasing its potential as an integrated platform enterprise [6][7] Product Innovations - The ALPHATRION® nanosecond pulse electric field ablation device utilizes a proprietary technology that enhances safety and efficacy in atrial fibrillation ablation procedures [7][14] - The StarTrek® three-dimensional dielectric mapping system is the first of its kind in China, approved by NMPA, providing high-resolution imaging comparable to CT scans [8][11] Strategic Importance - The investment addresses Xianjian's previous gap in the electrophysiology sector, enabling a complete clinical pathway from diagnosis to treatment [15][16] - The collaboration aims to create a domestic electrophysiology and structural heart solution alliance, enhancing competitiveness in the global market [16][17] Industry Trends - The integration of structural heart disease and atrial fibrillation treatment is becoming a trend, emphasizing the need for a comprehensive solution from identification to treatment [17][18] - The partnership between Xianjian and Jianhu is expected to drive the development of a domestic "arrhythmia treatment integrated platform," marking a significant step in the localization of electrophysiology technology [17][18]